FindTrial
Sign In

Plasma levels of vascular endothelial growth factor and matrix metalloproteinase after radiotherapy for cerebral arteriovenous malformations

Plasma levels of vascular endothelial growth factor and matrix metalloproteinase after radiotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCC-14005217
Enrollment
Unknown
Registered
2014-09-09
Start date
2014-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral arteriovenous malformation

Interventions

radiotherapy:receiving radiotherapy for cerebral AVM
control:No treatment

Sponsors

Huashan Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1)diagnosed as cerebral AVM and receiving radiotherapy; 2) within the age range of 16-60 years old;

Exclusion criteria

Exclusion criteria: 1)previously received treatments including surgery, interventional therapy and radiotherapy; 2)with any concomitant diseases.

Design outcomes

Primary

MeasureTime frame
VEGF;MMP-2;MMP-9;—

Countries

China

Contacts

Public ContactXu Hongzhi
xuhongzhi95@sina.com+86 13651932866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026